Peptide Receptor Radiotherapy for Aggressive Fibromatosis
Author Information
Author(s): De Pas T, Bodei L, Pelosi G, de Braud F, Villa G, Capanna R, Paganelli G
Primary Institution: European Institute of Oncology
Hypothesis
Can 90Y-DOTATOC be an effective treatment for recurrent aggressive fibromatosis?
Conclusion
90Y-DOTATOC treatment showed clinical benefits in patients with aggressive fibromatosis who were resistant to standard therapies.
Supporting Evidence
- 90Y-DOTATOC was well tolerated in patients with aggressive fibromatosis.
- Both patients showed clinical benefits with prolonged disease control after treatment.
- Neither acute nor late toxicity was observed in the treated patients.
Takeaway
Doctors used a special treatment called 90Y-DOTATOC to help two patients with a rare tumor that kept coming back, and it worked well without causing bad side effects.
Methodology
The study retrospectively examined aggressive fibromatosis specimens from patients and used OctreoScan to test for receptor expression before administering 90Y-DOTATOC.
Limitations
The study involved a small number of patients and was retrospective.
Participant Demographics
Two patients with recurrent aggressive fibromatosis were treated.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website